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a b s t r a c t
Langerhans cell histiocytosis (LCH) is a rare disease of neoplastic proliferation of monocyte–
macrophage system. Although LCH can affect almost any organ, solitary involvement of
jugular foramen is extremely rare and can present a diagnostic dilemma because of its rarity
at this location. Here, we present the case of an adult patient with LCH affecting the jugular
foramen, and review the relevant literature.
# 2014 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
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Langerhans cell histiocytosis (LCH), previously referred to as
histiocytosis X, is a rare disorder characterized by clonal
proliferation and excess accumulation of pathologic Langerhans
cells causing local or systemic effects [1,2]. The exact etiology of
LCH is still unknown. Clinical syndromes within this entity
include eosinophilic granuloma, Hand–Schüller–Christian dis-
ease, and Abt–Letterer–Siwe disease [2]. Langerhans cell histio-
cytosis typically occurs in childhood and adolescence as solitary
osteolytic lesions. The most frequent sites ofthe bony lesions are
the skull, femur, mandible, pelvis and spine [3]. A variety of
treatment modalities have been reported [4,5]. Here, we present
an adult female patient with LCH of the jugular foramen.
2. Case report
2.1. History
A 23-year-old female patient presented with a 6-week history
of occipital pain. There was no history of trauma or neoplasm.* Corresponding author at: Department of Neurosurgery, Shanghai Te
Tel.: +86 21 66307370; fax: +86 21 66307370.
E-mail address: kalantes@126.com (L. Meiqing).
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http://dx.doi.org/10.1016/j.pjnns.2013.12.008More recently, the patient complained of progressive stiffness
and weakness of neck, which impaired her range of neck
motion and caused torticollis. She must use cervical gear to
complete the daily activities. In the month prior to her
admission, her occipital pain increased with hoarseness of
voice and difﬁculty swallowing.
2.2. Examination
Neurologic examination was remarkable for marked im-
pairment of cervical ﬂexion, extension and rotation. The left
palate was mildly weak with diminution of the gag reﬂex.
Exceptionally, physical examination revealed a 3-cm, ﬁrm, and
regular lesion with normal overlaying skin in the left mastoid
process.
2.3. Investigation
Magnetic resonance imaging (MRI) demonstrated a homo-
geneous, 5.5 cm  3.5 cm solid mass involving the left
jugular foramen and lateral mass of atlas. The mass showed
low signal intensity on both T1- and T2-weighted images,
and intense heterogeneous enhancement following intrave-nth People's Hospital, Tongji University, Shanghai 200072, China.
blished by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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nography revealed occlusion of transverse and sigmoid
sinus. Computed tomography showed an irregular osteolytic
lesion of jugular foramen extending downwards lateral mass
of atlas (Fig. 1). The remainder of the examination was
unremarkable.
2.4. Surgery
A left far lateral approach was utilized to excise the lesion. A
surgical corridor was created by separating suboccipital
muscles and paravertebral muscle, drilling the left partial
occipital condyle. Exposure of the tumor demonstrated a gray,
yellow mass in the jugular foramen and lateral mass of atlas.
The lesion was easily separated, blood supply was moderate,
and ﬁnally tumor was partially resected. In order to restore
stability of the cervical spine, occipitocervical fusion was
performed.Fig. 1 – Post-gadolinium axial T1-weighted MR images (a–c) show
left jugular foramen with extension to the lateral mass of atlas. 
foramen and lateral mass of atlas.2.5. Histology
Gross examination of the surgical specimen revealed multiple,
irregular fragments of pale and tan soft tissue measuring in
aggregate 3 cm  2.1 cm  1.7 cm. Histological sections
revealed a granulomatous reaction pattern, with extensive
aggregates of histiocytes proliferation, which showed broad
cytoplasm cells and a kidney-shape nucleus, along with
clusters of eosinophils. Immunohistochemical stain by CD1a
antibody and S-100 immunoperoxidase stain were positive
only in the histiocytic cells. Because of the immunoexpression
of S-100 and CD1a by lesional cells, the diagnosis of LCH was
made (Fig. 2).
2.6. Postoperative course
The patient tolerated surgery well, without neurological deﬁcit
and with good recovery. In the ﬁrst month, MRI demonstrated an intensive heterogeneously enhancing mass affecting the
CT images (d–i) show bone destruction of the left jugular
Fig. 2 – Histologic examination shows tissue fragments composed of an eosinophil-rich infiltrate admixed with histiocytes (a).
The histiocytes are characterized by grooved, reniform nuclei (b). Histiocytic elements show diffuse, intense nuclear and
cytoplasmic reactivity for CD1a (c) and for S-100 protein (d).
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she received radiotherapy in a total dose of 10 Gy administrated
over ﬁve consecutive days to affected area. After 6 months of
follow-up, the patient denied recurrence of occipital pain and
neck stiffness, and resumed her routine activities and started
working (Fig. 3). Now, the patient continues to undergo serial
MRIs to monitor the residual tumor.
3. Discussion
The ﬁrst clinical description of LCH was published in 1865 by
Smith [6]. He described a case of a 4-year-old child who died of
whooping cough and was found at autopsy to have erythe-
matic changes on the skin and a few osteolytic foci in the
calvaria. Three years later, Paul Langerhans described epithe-
lial cells with long, dendrite-like processes. Langerhans
suggested that they might originate from bone marrow and
be a part of the immunological system [7]. There is now strong
evidence that proliferation of these cells was not only the
cause of Dr. Smith's patient's disorder, but was also one of LCH.
Langerhans cells are antigen-presenting histiocytes which
have a dendritic morphology by which their surface area
increases many folds in order to maximize the chance of
successful antigen presentation to speciﬁc subsets of T-cells
[1,2]. Lichtenstein named Langerhans histiocytosis as histio-
cytosis X in 1953 [8]. The letter ‘‘X’’ emphasized the unknown
etiology of diseases such as eosinophilic granuloma, Hand–
Schüller–Christian or Abt–Letterer–Siwe disease. In 1987, theWriting Group of the Histiocyte Society replaced the name
‘‘histiocytosis X’’ with the current term ‘‘Langerhans cell
histiocytosis’’ [9].
Langerhans cell histiocytosis is encountered mostly in the
pediatric population. The annual incidence in the pediatric age
range has been estimated at 2–5 per million per year. Most
cases are diagnosed before the age of 20 years, male slightly
more than females [10–12]. Hand–Schüller–Christian disease
involves multiple skeletal and extraskeletal lesions. Ten to
thirty percent of patients have the originally described
exophthalmos, polyuria, and skull lesions. Abt–Letterer–Siwe
disease is marked by widespread visceral involvement and
may have marked constitutional symptoms. It usually occurs
in infancy and often proves fatal as a result of multisystem
failure. Eosinophilic granuloma is classiﬁed as a unifocal bony
lesion, usually found in the calvaria, vertebral bodies, and long
bones, and rarely in the skull base [2,13,14].
In the skull base, petrous ridge of the temporal bone is the
most common site of LCH described [15]. Exceptionally, clivus,
sphenoid bone, petrous apex, infratemporal fossa involve-
ment have been documented in a few cases [12,14,16]. In our
patient, the unifocal osseous lesion extending from the left
jugular foramen to lateral mass of atlas has not previously
been reported.
The etiology of LCH is unknown. It is still debated whether
the proliferation of LCH is of neoplastic or reactive origin [2,11].
The clinical presentation of LCH involving skull base is widely
varied and is entirely dependent on the location, size and
extent of the lesion. These patients most commonly present
Fig. 3 – Axial post-gadolinium T1-weighted images (a–c) show reduction in size of the lesion. CT images show (d–f) occipital
fusion device, C2 pedicle screws, and C3 lateral mass screws in good position. Flexion–extension radiographs of cervical
spine (g–i). The patient is in a very good condition, and resumes her normal life 6 months after the operation (j–l).
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patient was mainly symptomatic with hoarseness of voice and
difﬁculty swallowing. Physical examination showed limitation
of cervical movement, local pain and swelling.
Imaging features of LCH lack speciﬁcity. Magnetic reso-
nance imaging appearance of LCH affecting skull base
includes abnormal signal with homogeneously or heteroge-
neously enhancing destructive soft tissue mass. It is
hyperintense on T2- and hypointense on T1-weighted
images. Due to the increased cellularity of the lesion,
diffusion restriction is often found [15,17]. Computed
tomography in thin slices is a very useful method in thediagnosis of this disease. It is more suitable for the
observation of local bone destruction [17]. Even so, the
other radiological differential diagnosis including chordoma,
neurinoma and glomus jugulare tumor must be considered
in jugular foramen region.
Clear diagnosis of LCH depends on histopathological tests.
Langerhans cell histiocytosis can be readily recognized on or
suggested by hematoxylin and eosin examination, where a
mixture of inﬂammatory cells is present, including macro-
phages, lymphocytes, plasma and Langerhans cells. The latter
is characterized by slight eccentric, ovoid, reniform or
convoluted cuclei. Immunohistochemistry conﬁrms positive
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demonstrated by electron microscopy are also characteristic
changes of LCH in the cytoplasm [18,19].
The treatment of patients with LCH varied widely
according to the extent of the disease. Surgery, radiotherapy,
and chemotherapy may be utilized separately or in combi-
nation [11]. Surgical treatment is primarily advocated for
isolated lesions. Some studies, moreover, considered that
non-radical removal might result in higher incidence of
relapses and extensive surgery with healthy bone margin
resection is a better choice. Unless the lesion is totally
curettage, to avoid recurrence, adjuvant radiotherapy must
be carried out after surgery [20]. Treatment of extensive
diseases (Hand–Schüller–Christian disease and Abt–Letterer–
Siwe disease) is much more complex. Corticosteroids,
methotrexate, vinblastine, growth hormones, interferon
alpha, cytosine arabinoside and low-dose radiotherapy in
combination or alone has shown some modest success
[21,22].
It has been 6 months since our patient's surgery. She is in a
very good condition, resumes her normal life, and continues to
undergo serial MRIs to monitor the residual tumor.
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